141836-47-7

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 13380-84-2 4-(hydroxymethyl)cyclohexane-1-carboxylic acid 
• 105-08-8 bis-1,4-(hydroxymethyl)cyclohexane 
• 141836-50-2 trans-[4-(tert-butyl-dimethyl-silanyloxymethyl)-cyclohexyl]-methanol 

Downstream Products

• 672314-42-0 (S)-N-[4'-(tert-butyldimethylsilyloxymethylcyclohexyl)methylidene]-1-amino-2-(methoxymethyl)pyrrolidine 
• 672314-48-6 (R)-N-[4'-(tert-butyldimethylsilyloxymethylcyclohexyl)methylidene]-1-amino-2-(methoxymethyl)pyrrolidine 
• 671815-85-3 N-[4'-(tert-butyldimethylsilyloxymethyl-cyclohexyl)methylidene]benzylamine 
• 129830-38-2 (-)-Y-27632 
• 786659-19-6 {1-[4-(pyridin-4-ylcarbamoyl)-cyclohexyl]-but-3-enyl}-carbamic acid tert-butyl ester 
• 671816-05-0 (S)-trans-4-[N'-(tert-butyloxycarbonyl)ethan-1'-amino]-N-(4''-pyridyl)cyclohexanecarboxamide 
• 671816-04-9 trans-tert-butyl (R)-1-[4-(pyridin-4-ylcarbamoyl)cyclohexyl]ethylcarbamate 
• 672314-45-3 (1R,1'R)-N-[1'-(phenyl)ethyl]-1-[4-(tert-butyldimethylsilyloxymethyl)cyclohexyl]ethan-1-amine 

Relevant academic research and scientific papers

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

IMIDAZOLE COMPOUND

Disclosed is an imidazole compound, in particular, the compound as shown in formula (I) and a pharmaceutically acceptable salt or tautomer thereof are disclosed.

SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF

The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

Synthesis and evaluation of 4-(1-aminoalkyl)-N-(4-pyridyl) cyclohexanecarboxamides as Rho kinase inhibitors and neurite outgrowth promoters

The influence of stereochemistry and alkyl side chain length on the bioactivity of the Rho kinase inhibitor Y-27632 [(+)-1, R = Me] was examined by the synthesis of (+)- and (-)-1, and two alkyl chain analogs (+)- and (-)-2 (R = n-propyl) and (-)-3 (R = n

1,4-SUBSTITUTED CYCLOHEXANE DERIVATIVES

Allylic compounds represented by the formula (I) are provided, wherein each of R1 to R8, m, n, A and X are as defined in the Specification. These compounds can inhibit Rho kinase, and can find utility in repair of damaged nerves in the central and peripheral nervous system by inducing axon growth and regeneration, and in the treatment by inhibition of Rho kinase in disease states in which Rho kinase is implicated. The compounds are relatively cell permeable and pharmaceutical compositions thereof can promote neurite growth and are also useful for the prevention of cell proliferation in malignant deseases.